Evidence map›Paper›PMID 40052805›Full record

ArticleJournal of clinical microbiology2025

Clinical significance and antifungal susceptibility profile of 103 clinical isolates of

Mary M Czech, Jennifer Cuellar-Rodriguez, Kyung J Kwon-Chung, Frida Stock, Chioma I Aneke, Kenneth N Olivier, Kevin P Fennelly, Juan Gea-Banacloche, Christa S Zerbe, Alexandra F Freeman and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Non-Candida fungal cholecystitis - an uncommon occurrence even in the right host.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  2. Antifungal exposure inAntimicrobial agents and chemotherapy · 2026
    Article
  3. Article
  4. Delayed cerebral abscess caused byMedical mycology case reports · 2026
    Article
  5. JSES reviews, reports, and techniques · 2026
    Article
  6. Article
  7. Successful use of olorofim for the treatment ofAntimicrobial agents and chemotherapy · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mary M CzechLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jennifer Cuellar-RodriguezLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Kyung J Kwon-ChungLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-6671-0994
Frida StockMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Chioma I AnekeMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Kenneth N OlivierDivision of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Kevin P FennellyPulmonary Clinical Medicine Section, Cardiovascular Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Juan Gea-BanaclocheLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Christa S ZerbeLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Alexandra F FreemanLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Steven M HollandLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Michail S LionakisLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-4994-9500
Amir SeyedmousaviMicrobiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6194-7447

Funding

Molecular Epidemiology of Clinically Important Fungi and Pathobiology of Fungal InfectionsZIACL090088 · CLC · CLINICAL CENTER · PI SEYEDMOUSAVI, AMIR · 2022 to 2025
$0k
HHS | National Institutes of Health (NIH) Intramural_ZIA CL090088 to Amir SeyedmousaviIntramural NIH HHS ZIA CL090088
6 · The paper itself

Abstract

Reduced susceptibility to antifungals is common among members of genera

Indexed as

Antifungal AgentsAscomycotaMycosesScedosporiumAdolescentAdultAgedChildChild, PreschoolClinical RelevanceDrug Resistance, FungalFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedAntifungal AgentsTriazolesantifungal susceptibility testingclinical outcomesLomentospora prolificansScedosporium species

Identifiers

PMID40052805
PMCPMC11980389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.